{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:16:46Z","timestamp":1789514206159,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.semarthrit.2015.05.006","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T10:51:45Z","timestamp":1432205505000},"page":"238-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review"],"prefix":"10.1016","volume":"45","author":[{"given":"Gabriele","family":"Simonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.05.006_bib1","first-page":"509","article-title":"Epidemiology of uveitis","volume":"140","author":"Wakefield","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib2","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of non-infectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologic: Targets and Therapy"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09273948.2012.723107","article-title":"Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis","volume":"21","author":"Cordero-Coma","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2010.05.008","article-title":"Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis","volume":"40","author":"Pato","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib6","article-title":"Current evidence of anti-TNF\u03b1 treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs","author":"Simonini","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajo.2004.12.009","article-title":"Improving the reporting of clinical case series","volume":"139","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.130206","article-title":"Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement","volume":"41","author":"Pelegrin","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u05f3s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al","volume":"63","author":"Elhai","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis","volume":"249","author":"Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib15","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et\u05f3s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib19","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/art.22966","article-title":"NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort","volume":"56","author":"Ar\u00f3stegui","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/acr.20357","article-title":"Author comment to Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u05f3s disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.semarthrit.2015.05.006_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory disease","volume":"84","author":"Dick","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Beh\u00e7et\u05f3s\u05f3 syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib26","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis\u2014a case report","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","article-title":"Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome","volume":"91","author":"Teoh","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","article-title":"Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient","volume":"22","author":"Tsang","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with Rituximab","volume":"18","author":"Saddredini","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1869-5760-3-56","article-title":"Anterior uveitis secondary to type II essential cryoglobulinemia","volume":"3","author":"Nicholson","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket486","article-title":"Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation","author":"Alejandre","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib32","first-page":"968180","article-title":"Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab","volume":"2012","author":"Oshitari","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib33","first-page":"101","article-title":"Remission induction in a case of refractory Beh\u00e7et\u05f3s disease with Alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib34","unstructured":"Suhler EB, Giles TR, Hanel SA, et al. A phase I\/II dose-ranging, randomized clinical trial of Abatacept (Orencia) in the treatment of refractory non-infectious uveitis: preliminary results. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting. Washington, USA; May 5-9, 2013."},{"key":"10.1016\/j.semarthrit.2015.05.006_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u05f3s disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","article-title":"Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach","volume":"52","author":"Simonini","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2010.05.017","article-title":"Current therapeutic approaches to autoimmune chronic uveitis in children","volume":"9","author":"Simonini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2015.05.006_bib38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/acr.21674","volume":"64","author":"Heiligenhaus","year":"2012","journal-title":"Arthritis Care Res"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T12:54:22Z","timestamp":1537620862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0049017215001122"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}